S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:VCYT

Veracyte (VCYT) Stock Forecast, Price & News

$22.33
-0.58 (-2.53%)
(As of 09/29/2023 ET)
Compare
Today's Range
$22.17
$23.41
50-Day Range
$22.47
$28.62
52-Week Range
$14.92
$32.40
Volume
727,452 shs
Average Volume
648,741 shs
Market Capitalization
$1.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.60

Veracyte MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
37.1% Upside
$30.60 Price Target
Short Interest
Bearish
3.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.70mentions of Veracyte in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$305,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.52) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

525th out of 972 stocks

Medical Laboratories Industry

13th out of 24 stocks


VCYT stock logo

About Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

VCYT Price History

VCYT Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Veracyte Inc (VCYT)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Here's Why This Little-Known Growth Stock Is a Buy
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Company Calendar

Last Earnings
8/08/2023
Today
9/29/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCYT
Employees
787
Year Founded
2006

Price Target and Rating

Average Stock Price Forecast
$30.60
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+37.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-36,560,000.00
Pretax Margin
-8.73%

Debt

Sales & Book Value

Annual Sales
$296.54 million
Book Value
$14.98 per share

Miscellaneous

Free Float
70,859,000
Market Cap
$1.63 billion
Optionable
Optionable
Beta
1.32

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Marc A. StapleyMr. Marc A. Stapley (Age 53)
    CEO & Director
    Comp: $1.25M
  • Ms. Rebecca  ChambersMs. Rebecca Chambers (Age 45)
    Exec. VP & CFO
    Comp: $772.41k
  • Ms. Annie McGuire (Age 42)
    Exec. VP, Gen. Counsel & Chief People Officer
    Comp: $633.65k
  • Mr. Jonathan Wygant (Age 52)
    VP & Chief Accounting Officer
  • Mr. Steven French
    Sr. VP & Chief Information Officer
  • Ms. Tracy Morris
    VP of Global Corp. Communications
  • Mr. Robert Brainin (Age 51)
    Exec. VP & Chief Bus. Officer
  • Dr. Fabienne Hermitte Ph.D.
    Sr. VP of Global Quality & Regulatory Affairs
  • Dr. John Leite Ph.D.
    Chief Commercial Officer for CLIA Bus.
  • Ms. Corinne Danan
    Sr. VP and GM of Biopharma & IVD Services













VCYT Stock - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price forecast for 2023?

6 Wall Street research analysts have issued 1 year target prices for Veracyte's stock. Their VCYT share price forecasts range from $23.00 to $35.00. On average, they anticipate the company's share price to reach $30.60 in the next twelve months. This suggests a possible upside of 37.0% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How have VCYT shares performed in 2023?

Veracyte's stock was trading at $23.73 at the beginning of the year. Since then, VCYT shares have decreased by 5.9% and is now trading at $22.34.
View the best growth stocks for 2023 here
.

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our VCYT earnings forecast
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) released its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.04. The biotechnology company had revenue of $90.32 million for the quarter, compared to analysts' expectations of $83.05 million. Veracyte had a negative net margin of 8.84% and a negative trailing twelve-month return on equity of 2.71%. The company's revenue was up 24.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.13) earnings per share.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $342.00 million-$350.00 million, compared to the consensus revenue estimate of $335.77 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $22.34.

How much money does Veracyte make?

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.63 billion and generates $296.54 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Veracyte have?

The company employs 787 workers across the globe.

Does Veracyte have any subsidiaries?
The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.
Read More
How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -